The medical journal The Lancet has released the results of a trial for Russia's single-dose vaccine Sputnik Light.
The Russian Direct Investment Fund (RDIF) stressed in a press release on Wednesday that the publication is further proof that Sputnik Light "demonstrates a high safety profile and induces a strong humoral and cellular immune response".
The open label, prospective, non-randomised phase 1/2 trial was aimed to assess the safety, tolerability, and immunogenicity of the Sputnik Light vaccine. It was carried out at a single clinical site in Russia's St. Petersburg, involved 110 enrolled participants and was sponsored by the Russian Direct Investment Fund.
"Overall incidence of solicited adverse reactions was 74 (67.2%) of 110 participants. Some volunteers had several adverse events of different degrees of severity. Most of the registered, solicited systemic and local adverse reactions were mild (73 [66.4%]). Only 6 participants (5.5%) had adverse events of moderate grade in severity. No serious adverse events were reported", the study reads.
Sputnik Light is a single-component COVID-19 vaccine (the first component of the Sputnik V vaccine) that has been authorised in more than 15 countries, with the registration process ongoing in a further 30 nations.
Sputnik V is the world's first vaccine against COVID-19. It has shown 91.6 percent efficacy and has been approved for use in 70 countries, representing a total population of four billion people, or 50 percent of the world's populace.